Synexus and Radiant Research Announce Merger
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees. The enlarged entity will retain the Synexus name.
“We are delighted to be working together with the Radiant team,” said Christophe Berthoux, who has been chief executive officer for Synexus since 2010 and will lead the new company. “Best practices from Synexus, Radiant and our earlier acquisition of Research Across America will be incorporated across our global network of sites.”
Mike Clay will lead the U.S. operations of the combined business, reporting directly to Berthoux.
The new business will span 11 countries, offering access to more than 100 million patients in clinical development markets, and it will provide data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe and Africa, according to Synexus.
Philip Ward is the European Editor for Applied Clinical Trials
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
